FG Cardio Arrhythmia
Pharmacogenetics of arrhythmias
The arrhythmia consists of a change in heart rhythm that can slow down, speed up or deregulate the heartbeat. This change is usually due to changes in the electrical conduction system of the heart and may lead to palpitations, syncope or cardiac arrest. Despite the latest advances in the pharmacological treatment of arrhythmias, not all patients respond well to antiarrhythmics and some of these drugs can lead to side effects. The lack of tolerance and effect of the pharmacological treatment of the arrhythmias may be in large part due to genetic causes, since the variation in the human genome is one of the most important factors responsible for modulating the individual response to the medications.
The genetic profile FG – Cardio Arrhythmia studies the main metabolizing enzymes and targets that are implicated in the effect and toxicity of the different pharmacological treatments of arrhythmias. The analysis provides relevant information about the 5 most used drugs from the study of 14 genetic polymorphisms described in the scientific literature.
• Patients on pharmacological treatment who wish to customize medication based on their genetic profile.
• Patients with drug side effects.
• Patients in whom pharmacological treatments do not show the expected results.
Next Generation Sequencing (NGS)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent.
• Clinical Questionnaire.
• Fasting is not necessary for the test.